Sanofi (SNY) Non-Current Assets (2009 - 2026)
Sanofi (SNY) posted Non-Current Assets of $114.6 billion for Q1 2026, up 2.68% sequentially from $111.6 billion in Q4 2025, and up 23.95% YoY from $92.4 billion in Q1 2025.
Sanofi (SNY) Non-Current Assets (2009 - 2026) Analysis & Trends
Sanofi (SNY) has 18 years of Non-Current Assets data on file, last reported at $114.6 billion in Q1 2026.
- Quarterly Non-Current Assets rose 23.95% year-over-year to $114.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $114.6 billion (up 23.95% YoY) and the FY2025 annual result came in at $111.6 billion, up 15.75% from the prior year.
- Non-Current Assets advanced to $114.6 billion in Q1 2026 per SNY's latest filing, from $111.6 billion in the prior quarter.
- The five-year high for Non-Current Assets was $114.6 billion in Q1 2026, with the low at $92.4 billion in Q1 2025.
- Average Non-Current Assets over 5 years is $103.1 billion, with a median of $103.1 billion recorded in 2023.
- Year-over-year, Non-Current Assets slipped 7.81% in 2022 and climbed 23.95% in 2026.
- Sanofi's Non-Current Assets stood at $94.5 billion in 2022, then advanced by 9.08% to $103.1 billion in 2023, then fell by 6.47% to $96.4 billion in 2024, then grew by 15.75% to $111.6 billion in 2025, then advanced by 2.68% to $114.6 billion in 2026.
- Business Quant data shows SNY's Non-Current Assets at $114.6 billion in Q1 2026, $111.6 billion in Q4 2025, and $111.9 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 61.74 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 141.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 102.93 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 84.40 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Sanofi | - | - | 9.49 Bn | 114.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 114.57 Bn |
| Dec 31, 2025 | 111.58 Bn |
| Sep 30, 2025 | 111.94 Bn |
| Jun 30, 2025 | 99.55 Bn |
| Mar 31, 2025 | 92.43 Bn |
| Dec 31, 2024 | 96.40 Bn |
| Jun 30, 2024 | 107.34 Bn |
| Dec 31, 2023 | 103.07 Bn |
| Jun 30, 2023 | 103.57 Bn |
| Dec 31, 2022 | 94.49 Bn |
| Jun 30, 2022 | 99.43 Bn |
| Dec 31, 2021 | 102.49 Bn |
| Jun 30, 2021 | 99.62 Bn |
| Dec 31, 2020 | 96.13 Bn |
| Jun 30, 2020 | 89.15 Bn |
| Dec 31, 2019 | 667.01 Mn |
| Jun 30, 2019 | 95.69 Bn |
| Dec 31, 2018 | 99.03 Bn |
| Jun 30, 2018 | 104.20 Bn |
| Mar 31, 2018 | 100.61 Bn |